 NEW YORK, Nov. 02, 2022 GLOBE NEWSWIRE -- SELLAS Life Sciences Group, Inc. NASDAQ: SLS SELLAS or the Company, a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S GPS in patients with acute myeloid leukemia. 